CD274 and melanoma: This knowledge has finally led to a new immune-based therapeutic approach using monoclonal antibodies directed against CTLA-4 and PD-1/PD-L1, which have been approved for a variety of different cancers such as melanoma, lung cancer, head and neck cancer, and renal cell carcinoma, with ongoing research to find new immune targets [16].